Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| TS TSBXTurnstone Biologics | $0.36+0.0% | $8.2M | 1 assetsStage unavailable | No dated catalyst | |
| TS TSHATaysha Gene Therapies | $6.09-0.3% | $1.98B | 5 assetsStage unavailable | No dated catalyst | |
| TS TSVT2seventy Bio | $5.00+0.0% | $266.1M |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
4 assetsStage unavailable |
| No dated catalyst |
| TT TTRXTurn Therapeutics Inc. | $9.46-0.8% | $287.3M | 2 assetsStage unavailable | No dated catalyst |
| TV TVTXTravere Therapeutics | $65.71+1.9% | $6.19B | 6 assetsPhase 3 | Pegtibatinase (TVT-058)Phase 3 · Data readout |
| TX TXMDTherapeuticsMD | $2.06+0.0% | $23.8M | 3 assetsStage unavailable | No dated catalyst |
| TY TYRATyra Biosciences | $26.05+1.4% | $1.55B | 6 assetsPhase 2 | TYRA-300Phase 2 · Data readout |
| UN UNCYUnicycive Therapeutics | $5.63+3.3% | $154.2M | 2 assetsNDA | No dated catalyst |
| UP UPBUpstream Bio | $6.97+1.8% | $381.8M | 3 assetsPhase 2 | VerekitugPhase 2 · Data readout |
| UR URGNUroGen Pharma | $46.86+0.1% | $2.29B | 7 assetsStage unavailable | No dated catalyst |
| UT UTHRUnited Therapeutics | $513.12-1.5% | $22.01B | 12 assetsPhase 3 | miroliverELAPPhase 1 · Data readout |
| VA VALNValneva SE | $6.96+2.1% | $660.0M | 7 assetsPhase 2 | Shigella4V2 (S4V2) Phase 2 · Data readout |
| VA VAXXVaxxinity, Inc. | $0.00+0.0% | $12,678 | 2 assetsStage unavailable | No dated catalyst |
| VB VBIVVBI Vaccines | $0.07+0.0% | $1.9M | 7 assetsStage unavailable | No dated catalyst |
| VC VCELVericel | $42.68+1.4% | $2.19B | 4 assetsStage unavailable | No dated catalyst |
| VC VCNXVaccinex | $1.10+0.0% | $2.9M | 4 assetsStage unavailable | No dated catalyst |
| VE VERAVera Therapeutics | $32.28+3.2% | $2.33B | 5 assetsApproved | AtaciceptPhase 2a · Data readout |
| VE VERUVeru Pharma | $2.64+2.3% | $45.0M | 10 assetsStage unavailable | No dated catalyst |
| VE VERVVerve Therapeutics | $11.13+0.0% | $994.0M | 3 assetsStage unavailable | No dated catalyst |
| VI VIGLVigil Neuroscience | $8.05+0.0% | $375.7M | 2 assetsStage unavailable | No dated catalyst |
| VI VIRVir Biotechnology | $9.78+6.2% | $1.65B | 11 assetsPhase 3 | Tobevibart + ElebsiranPhase 3 · Data readout |
| VK VKTXViking Therapeutics | $33.89-1.4% | $3.95B | 6 assetsPhase 3 | VK2735 (Injectable) Phase 3 · Data readout |
| VN VNDAVanda Pharmaceuticals Inc. | $5.28-1.9% | $319.2M | 23 assetsPDUFA | Imsidolimab (IL-36 Inhibitor)PDUFA · Approval decision |
| VO VORVor Biopharma | $23.36+1.3% | $1.38B | 6 assetsPhase 3 | TelitaciceptPhase 3 · Data readout |
| VR VRCAVerrica Pharmaceuticals | $4.82-0.8% | $82.8M | 3 assetsPhase 3 | YCANTH (VP-102)Phase 3 · Data readout |
| VR VRDNViridian Therapeutics | $24.29-0.9% | $2.75B | 6 assetsApproved | VRDN-008Phase 1 · Data readout |
| VR VRNAVerona Pharma ADR | $106.91+0.0% | $9.09B | 5 assetsStage unavailable | No dated catalyst |
| VR VRTXVertex Pharmaceuticals Incorporated | $548.05+1.4% | $138.91B | 27 assetsPDUFA | PovetaciceptPDUFA · Approval decision |
| VS VSTMVerastem Oncology | $6.89+1.0% | $624.0M | 10 assetsPhase 1/2 | GFH375 (VS-7375)Phase 1/2 · Data readout |
| VT VTGNVistaGen Therapeutics | $0.24+1.2% | $10.8M | 7 assetsStage unavailable | No dated catalyst |
| VT VTRSViatris Inc | $16.32+2.0% | $18.75B | 13 assetsApproved | MR-141 (phentolamine ophthalmic solution 0.75%) PDUFA · Approval decision |
| VT VTVTvTv Therapeutics | $33.26+0.5% | $131.5M | 5 assetsPhase 3 | Cadisegliatin (TTP399) Phase 3 · Data readout |
| VT VTYXVentyx Biosciences | $14.00+0.0% | $1.00B | 6 assetsStage unavailable | No dated catalyst |
| VX VXRTVaxart Inc. | $0.52+0.0% | $126.3M | 6 assetsPhase 2b | Second Generation Oral Norovirus VaccinePhase 1 · Data readout |
| VY VYGRVoyager Therapeutics | $3.39+2.1% | $208.9M | 11 assetsPhase 1a | VY7523 (formerly VT- TAU01) [anti-tau antibody]Phase 1a · Data readout |
| VY VYNEVYNE Therapeutics Inc | $28.56+0.0% | $19.1M | 6 assetsStage unavailable | No dated catalyst |
| WH WHWKWhitehawk Therapeutics | $4.73-2.1% | $269.7M | 3 assetsPhase 1 | HWK-016 (MUC16 Targeted ADC)Phase 1 · Data readout |
| WV WVEWave Life Sciences | $5.29+0.8% | $1.04B | 8 assetsStage unavailable | No dated catalyst |
| XB XBITXBiotech | $2.28-1.3% | $69.5M | 8 assetsStage unavailable | No dated catalyst |
| XC XCURExicure | $1.15-11.5% | $7.5M | 1 assetsStage unavailable | No dated catalyst |